Biotech firm Cocrystal Pharma is dedicated to researching and creating antiviral therapeutics for serious and chronic viral illnesses. With a focus on hepatitis C virus (HCV), influenza, coronavirus, and norovirus infections, Cocrystal Pharma utilizes structure-based technologies to develop antiviral medications. The firm is undergoing clinical trials for its HCV non-nucleoside polymerase inhibitor, CC-31244, after completing Phase II, and is working on preclinical development trials for its PB2 inhibitor, CC-42344, for influenza infection. Additionally, Cocrystal Pharma is actively identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. The company has collaborations and agreements with Merck Sharp & Dohme Corp, Kansas State University Research Foundation, HitGen, and InterX Inc to develop treatments for various infections. Cocrystal Pharma is headquartered in Bothell, Washington.